缺血性卒中与缺血性心脏疾病的抗血小板治疗.ppt.pptVIP

* Data from the CAPRIE trial show that clopidogrel: reduced the rate of MI, stroke and vascular death in patients with a recent MI, recent stroke, or established PAD1 offered amplified benefits in patients with additional risk factors (diabetes, hypercholesterolemia)1 had a safety profile comparable to that of ASA1 reduced the rate of vascular events in low- and high-risk patients than ASA1–5 reduced MI, stroke, vascular death and hospitalizations event rate/year.5 References CAPRIE Steering Committee. Lancet 1996; 348: 1329–1339. Jarvis B, et al. Drugs 2000; 60: 347–377. Ringleb PA, et a